| Literature DB >> 17102944 |
Gloris Sánchez1, Julio S Castro, Soham Al Snih, Luísa Pérez Blanco, María H Esteva, Ernesto García Macgregor, Marielena González, Ysabel Granados, Francisco Marín, Alexis Rosas, Antonio Tristano, Esther Chirinos, Luís Mundaraín, Gilberto Sanoja, Guisela Zambrano-Marín, Martín A Rodríguez.
Abstract
A multicenter, national, retrospective, and cross-sectional study of 219 hospital-based Venezuelan patients with rheumatoid arthritis (RA) was aimed to evaluate the probability of continuity of treatment with oral methotrexate (MTX). Treatment survival decreased from 92% at 12 months to 42% at 180 months, as assessed by life table analysis and the Kaplan-Meier method. Forty-seven patients stopped treatment and adverse effects (29.7%) and lack of continuous access to medication (19.1%) were the most common causes for withdrawal. MTX survival was decreased in the group with combined MTX plus leflunomide therapy, as shown by the log-rank test. Venezuelan patients with RA have a probability of continuing treatment with oral MTX comparable to non-Hispanic patient populations. However, concomitant use of leflunomide may increase the risk of interruption of MTX treatment in this RA population.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17102944 DOI： 10.1007/s00296-006-0261-x
Source DB: PubMed Journal: Rheumatol Int ISSN： 0172-8172 Impact factor: 2.631